Biogen BIIB

NAS: BIIB | ISIN: US09062X1037   17/05/2024
230,57 USD (+0,23%)
(+0,23%)   17/05/2024

16 mei 2024 · Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis · Persbericht

16 mei 2024 · Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis · Persbericht

15 mei 2024 · Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status · Persbericht

15 mei 2024 · Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status · Persbericht

25 april 2024 · Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA® · Persbericht

1 april 2024 · Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA · Persbericht

6 maart 2024 · New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy · Persbericht

4 maart 2024 · Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual Meeting · Persbericht

23 februari 2024 · Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP · Persbericht

12 februari 2024 · Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia · Persbericht

31 januari 2024 · Biogen to Realign Resources for Alzheimer's Disease Franchise · Persbericht

19 december 2023 · Centralized Marketing Authorizations of Generic Versions of TECFIDERA® are Revoked by the European Commission · Persbericht

15 december 2023 · CHMP Issues Positive Opinion for Biogen’s SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia, a Rare Neurodegenerative Disease · Persbericht

14 december 2023 · ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S. · Persbericht

6 november 2023 · Biogen Appoints Monish Patolawala to its Board of Directors · Persbericht

25 oktober 2023 · Eisai Presents New LEQEMBI® (lecanemab-irmb) Investigational Subcutaneous Formulation Interim Study Results and Clinical Improvement Data in Earlier Stages of Early Alzheimer’s Disease From Additional Analyses of Clarity AD at The Clinical Trials On Alzheimer’s Disease (CTAD) Conference · Persbericht

25 oktober 2023 · Eisai Presents New Leqembi® (Lecanemab-Irmb) Investigational Subcutaneous Formulation Interim Study Results And Clinical Improvement Data In Earlier Stages Of Early Alzheimer's Disease From Additional Analyses Of Clarity Ad At The Clinical Trials On Alzheimer's Disease (Ctad) Conference · Persbericht

25 oktober 2023 · New Data from Biogen’s Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer’s Disease · Persbericht

24 oktober 2023 · LEQEMBI® (lecanemab-irmb) NAMED ONE OF TIME's BEST INVENTIONS OF 2023 · Persbericht

19 oktober 2023 · Biogen to Present New Data at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Meeting · Persbericht

Mijn selecties